Ontario launches two new publicly funded prenatal screening tests
Ontario is introducing two new publicly funded prenatal screening tests designed to improve care for pregnancies and reduce unnecessary medical treatments.
BORN Ontario and Prenatal Screening Ontario announced the new blood tests as part of the province’s $9.8-million investment in prenatal screening services.
The tests use a blood sample from a pregnant person to determine the fetus’s blood type, helping doctors discover pregnancies that need additional treatment or monitoring.
The two new tests include:
- Fetal RHD screening: Helps determine whether RhD-negative pregnant people require RhD immune globulin (RhIG), a treatment used to prevent complications caused by incompatible blood types.
- Alloimmunized fetal blood group genotyping: Helps guide monitoring and care for pregnant people with certain antibodies that could pose risks to their babies.
Being RhD-negative means your red blood cells do not have a specific inherited protein called the Rhesus D (RhD) antigen.
Before these screenings were available, all RhD-negative people got RhIG treatment regardless of their fetus’s blood type.
The new screening allows doctors to determine whether that treatment is needed, reducing unnecessary interventions and helping conserve RhIG, a blood product that is in limited supply.
“Our government is ensuring Ontario families have access to innovative and world-class prenatal care,” said Health Minister Sylvia Jones. “The introduction of non-invasive fetal blood type screening is another step forward in providing expectant parents with the best possible care while strengthening Ontario’s leadership in pregnancy and newborn health.”
The tests will also help identify pregnancies at risk of hemolytic disease of the fetus and newborn (HDFN), a potentially serious condition in which maternal antibodies attack a baby’s red blood cells.
“By better identifying which pregnancies require intervention and monitoring, we can tailor care more effectively and improve outcomes for both pregnant individuals and babies,” said Dr. Barbra de Vrijer, Maternal-Fetal Medicine Specialist.






